bsm-51714M [Primary Antibody]
RIPK3 Monoclonal Antibody
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Mouse

Target Protein: RIPK3

Clonality: Monoclonal

Entrez Gene: 11035

Swiss Prot: Q9Y572

Source: Recombinant human RIPK3.

Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background:

Essential for programmed necrosis in response to death-inducing TNF-alpha family members. Upon induction of necrosis, RIPK3 interacts with, and phosphorylates RIPK1 to form a necrosis-inducing complex. RIPK3 binds to and enhances the activity of three metabolic enzymes: GLUL, GLUD1, and PYGL. These metabolic enzymes may eventually stimulate the tricarboxylic acid cycle and oxidative phosphorylation, which could result in enhanced ROS production.

Size: 100ul

Concentration: 0.5ug/ul

Applications: WB=1:500-1000，

Predicted Molecular Weight: 57


Predicted Cross Reactive Species: Human

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Shasha Chen. et al. Quercetin alleviates zearalenone-induced apoptosis and necroptosis of porcine renal epithelial cells by inhibiting CaSR/CaMKII signaling pathway. FOOD CHEM TOXICOL. 2023 Nov;:114184Read more>>
  • Dan Zhao. et al. Copper exposure induces inflammation and PANoptosis through the TLR4/NF-B signaling pathway, leading to testicular damage and impaired spermatogenesis in Wilson disease. CHEM-BIOL INTERACT. 2024 Jun;396:11106Read more>>
  • Shuang Wang. et al. Dioscin exerts nephroprotective effects by attenuating oxidative stress and necroptosis-induced inflammation. INT IMMUNOPHARMACOL. 2024 Oct;140:112885Read more>>
VALIDATION IMAGES

Lane 1: HT-29 cell lysates; Lane 2: Jurkat cell lysates; Lane 3: SW620 cell lysates; Lane 4: THP-1 cell lysates; Lane 5: K562 cell lysates probed with RIPK3 Monoclonal Antibody, Unconjugated (bsm-51714M) at 1:1000 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.